Scarlet Therapeutics, a Bristol biotech startup, closing a £3.2m seed funding round after reporting preclinical evidence that its lab-grown universal red blood cells mature and circulate in vivo with a half-life comparable to donated blood. The funding and results aim to accelerate selection of a lead therapeutic candidate, in vivo proof-of-concept studies, manufacturing development and regulatory engagement, with potential implications for transfusion services, patients with rare blood types and therapeutic delivery for metabolic diseases.
The seed round was led by Eos Advisory, with participation from existing investor SCVC and new investors Oshen Bio (Switzerland & Luxembourg) and Daft Capital (US). The financing totals £3.2 million and is earmarked for platform development and early translational work. The company also announced three board appointments: John Beadle representing Eos Advisory, Didier Cowling from Oshen Bio, and Tim Sparey as independent Chair of the Board.
Read more HERE.
